Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has delivered a news-heavy quarter, recording revenues of US$3.4 million, with product revenue surging 300% year on year to US$1.2 million as FebriDx® momentum built in the US.
The company signed a six-year, US$317 million exclusive US distribution deal for FebriDx® with PHASE Scientific and submitted its CLIA waiver application to the FDA — two milestones that anchor the commercial pathway and near-term catalysts.
Operationally, Lumos generated an operating cash inflow of US$1.8 million and lifted quarter-end cash to US$4.5 million, supported by milestone and customer receipts; financial flexibility is further underpinned by an undrawn US$3.3 million shareholder loan facility.
Together, these outcomes point to strengthening fundamentals across products and services, with multiple levers in place ahead of expected FDA feedback on the CLIA waiver between November 2025 and February 2026.
“I am very encouraged with the progress Lumos has achieved during the quarter across our product, services and corporate initiatives. The completion and submission of the CLIA waiver application for FebriDx®, the execution of our exclusive US distribution agreement with PHASE Scientific, and the commencement of the BARDA-supported paediatric study all mark important milestones in advancing our strategy," CEO Doug Ward said.
"Lumos maintains a sound balance sheet with financial flexibility, supported by milestone receipts from BARDA, Hologic, payments under the PHASE Scientific agreement, and the flexible loan facility secured from major shareholders Tenmile and Ryder Capital. These initiatives position Lumos well as we await feedback from the FDA on our FebriDx® CLIA waiver submission. Overall, I am very pleased with the momentum we are building and confident in Lumos’ ability to execute on our strategy to deliver innovative, accessible diagnostic test solutions globally.
“Looking ahead, we remain firmly focused on our strategic priorities and committed to building a strong, sustainable business that delivers long-term value for patients, partners, and shareholders alike.”
Operational update
Quarterly revenue composition reflects two distinct engines. Services contributed US$2.2 million, with work active across ~12 external projects. The Hologic relationship remains the principal driver here, spanning an IP agreement and a multi-phase development program to migrate and modernise the fFN pre-term birth test on Lumos’ reader platform with improved connectivity.
Elsewhere, programs with Burnet Diagnostics Initiative, Huvepharma, TeleMedVet and Aptatek Biosciences continued. Product revenue reached US$1.2 million, a 300% year-on-year increase, underpinned by PHASE Scientific’s US$1.0 million exclusivity fee and expanding US usage of FebriDx®. Lumos is positioning CorDx’s combo Flu A/B/COVID test to replace the company’s own ViraDx®, which is no longer price competitive.
The operational cadence for FY26 centres on securing and scaling commercial channels for FebriDx® in the US, while protecting Services momentum through milestone execution and, where appropriate, scope expansions. In parallel, the company is navigating a staggered revenue profile in Services due to the amortisation changes on the Hologic IP payment, which reduced monthly recognition from US$0.5 million to US$0.16 million as the project timeline extended.
Development services & contract manufacturing (Hologic and others)
Lumos’ Hologic fFN program now spans three phases with nine milestones and added scope, taking total development milestone payments to US$6.0–6.4 million. Phase 1 (US$0.4 million) is complete. Phase 2 (US$2.5–2.7 million) covers assay feasibility: the first milestone is complete and the second — expanded in August 2025 — is nearing completion; US$1.8 million has been received for this phase, including US$1.3 million collected in October 2025. Phase 3 (US$3.1–3.3 million) covers system prototype delivery, with milestones 4 and 5 in progress and an additional hardware prototype scope added in March 2025.
Work to finalise Phase 2 is likely to delay some Phase 3 activities, extending the program timeline but preserving the milestone pathway. Outside Hologic, the follow-on contract with Aptatek Biosciences (approx. US$1.5 million, time-and-materials) advances PheCheck™, an in-home PKU monitoring tool, through design maturation, verification testing for clinical readiness, and future FDA submission support. Lumos anticipates further services and instrument manufacturing revenue as PheCheck™ progresses to clinical phases.
These service lines, alongside select contract manufacturing and licensing receipts, continue to complement the company’s growing proprietary product effort.
Products division – FebriDx® (commercial and regulatory)
The period was pivotal for FebriDx®. In July, Lumos signed a six-year exclusive US distribution agreement with PHASE Scientific, valued at US$317 million (A$487 million). Cash components include a US$1.0 million execution/exclusivity fee and US$1.0 million pre-paid purchase order on signing, a further US$1.5 million following CLIA waiver submission, and an additional US$5.0 million non-refundable pre-paid purchase order upon CLIA waiver grant.
In August, Lumos completed the CLIA waiver study and lodged its submission with the FDA, demonstrating >98% concordance between trained and untrained operators — a key threshold to support waived categorisation. BARDA milestone receipts of ~US$1.25 million were triggered by the submission, with one final BARDA payment (~US$0.51 million) contingent on CLIA waiver approval.
The company also engaged PRO-spectus to drive US market access and reimbursement expansion across major private payors (Medicare coverage already in place). BARDA exercised an option to fund a paediatric CLIA-waived study (ages 2–12) across ~20 US sites; the study commenced post-quarter with first patient tested and could run ~12 months, unlocking US$6.2 million in staged milestones as recruitment and regulatory events are achieved.
Women’s sexual health pipeline
Lumos is progressing a targeted portfolio of women’s sexual health point-of-care diagnostics aimed at high-need, high-access settings. Three candidates have advanced to technical feasibility, reflecting early proof-of-concept for assays and workflows on the company’s reader platforms. The near-term objective is to transition at least one program into formal product development within the next 6–8 months, with gating criteria focused on clinical utility, regulatory pathways, manufacturability, and commercial viability in ambulatory and primary-care environments.
The broader strategy is to leverage platform commonality — assay architecture, cartridge design, and connected readers — to compress development timelines and reduce cost-per-test at scale. This pipeline complements the company’s women’s health services work with Hologic, providing a longer-dated product avenue that could diversify revenue away from single-asset risk.
Management positions the category as structurally attractive: growing testing volumes, potential to shift care earlier in the pathway, and payer interest in cost-effective, rapid triage tools. Execution risks include feasibility-to-development transitions, clinical study resourcing, and reimbursement clarity; however, internal evidence-based stage-gating and external partnerships are intended to mitigate these factors as candidates mature.
Financing and liquidity
On September 9, 2025, Lumos executed definitive agreements for a secured A$5.0 million (US$3.3 million) shareholder loan facility with Tenmile and Ryder Capital, following a July term sheet.
The facility bears 15% interest on drawn amounts, matures 12 months from first draw with an option to extend a further 12 months, and was undrawn at quarter-end — providing contingent working capital coverage through and beyond the anticipated CLIA waiver decision. As part of the arrangement, each lender received 7.5 million Lumos shares for establishment and service fees.
Concurrently, Lumos terminated its prior convertible note facility, including the unused A$4.0 million second tranche. During the quarter, the company also received ~US$1.0 million from the exercise of 20.8 million options at A$0.0707 each by SBC Global Investment Fund, strengthening the cash position without incremental debt.
The net result is a materially improved liquidity profile: US$4.5 million cash on hand at September 30, 2025, plus US$3.3 million in undrawn committed debt, positioning the company to fund clinical, regulatory, and commercial initiatives over the coming quarters while limiting immediate dilution risk for shareholders.
Outlook and priorities
Near-term priorities are centred on US market access and regulatory milestones for FebriDx®. The company expects FDA feedback on the CLIA waiver between November 2025 and February 2026 and is preparing for commercial scale-up with PHASE Scientific, while expanding reimbursement coverage among large private insurers and targeted regional payors.
Operationally, Lumos will progress the BARDA-funded paediatric study, which commenced with first patient tested in October and could broaden the CLIA-waived label to ages 2–12, potentially expanding the US addressable market by ~15–20%. On the services side, the team aims to deliver Hologic Phase 2 (assay feasibility) completion and advance Phase 3 prototype milestones, acknowledging timeline adjustments due to added scope. Internally, at least one women’s health candidate is targeted to enter formal product development within 6–8 months.
Liquidity is supported by quarter-end cash and an undrawn facility, with additional milestone and purchase-order receipts possible upon regulatory progress.
Collectively, these actions are intended to sustain momentum, underpin revenue visibility and position the company for a stronger commercial run-rate into FY26.